Recurrent BRAF mutations in Langerhans cell histiocytosis
Brigham and Women's Hospital · Harvard University · +4 more institutions
Abstract
Langerhans cell histiocytosis (LCH) has a broad spectrum of clinical behaviors; some cases are self-limited, whereas others involve multiple organs and cause significant mortality. Although Langerhans cells in LCH are clonal, their benign morphology and their lack (to date) of reported recurrent genomic abnormalities have suggested that LCH may not be a neoplasm. Here, using 2 orthogonal technologies for detecting cancer-associated mutations in formalin-fixed, paraffin-embedded material, we identified the oncogenic BRAF V600E mutation in 35 of 61 archived specimens (57%). TP53 and MET mutations were also observed in one sample each. BRAF V600E tended to appear in younger patients but was not associated with…
Citation impact
- FWCI
- 20.90
- Percentile
- 100%
- References
- 22
Authors
15- GBGayane Badalian‐VeryCorresponding
Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute
- JVJo‐Anne Vergilio
Harvard University, Boston Children's Museum
- BDBarbara Degar
Harvard University, Dana-Farber Cancer Institute, Boston Children's Museum
- LELaura E. MacConaill
Dana-Farber Cancer Institute
- BBBarbara Brandner
Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute
Topics & keywords
- Langerhans cell histiocytosis
- Mutation
- Cancer research
- V600E
- Biology
- MAPK/ERK pathway
- Kinase
- Histiocytosis
- Good health and well-being